Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:ATCCode |
L01XX41
|
| gptkbp:CASNumber |
192185-72-1
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:hasInChIKey |
QXJYYZQXQZJHKK-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C27H22Cl2N6O
|
| gptkbp:hasSMILES |
C1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C(=O)NCC4=NC5=CC=CC=C5N4C6=CC=CC=C6.Cl.Cl
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| gptkbp:isFarnesyltransferaseInhibitor |
true
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
inhibits farnesyltransferase enzyme
|
| gptkbp:molecularWeight |
533.41 g/mol
|
| gptkbp:otherName |
Tipifarnib
|
| gptkbp:PubChem_CID |
148192
CHEMBL19021 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Zarnestra
|
| gptkbp:usedForTreatmentOf |
gptkb:acute_myeloid_leukemia
solid tumors |
| gptkbp:bfsParent |
gptkb:tipifarnib
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
R115777
|